CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies

In multiple myeloma (MM), the anti-CD38 monoclonal antibody Daratumumab has become essential in the therapeutic arsenal, although very few predictive factors of response to Daratumumab have been identified in clinical studies. We have prospectively collected biological data from 97 patients treated...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Djamila Chemlal, Camille Pochard, Valentin Jacquier, Angélique Bruyer, Ludovic Gabellier, Léa Fornero, Clément Vempère, Amélie Machura, Guilhem Requirand, Nicolas Robert, Caroline Bret, Guillaume Cartron, Laure Vincent, Hugues de Boussac, Jérôme Moreaux, Charles Herbaux
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2025-12-01
Edice:	OncoImmunology
Témata:	Myeloma immunotherapies resistance CD200
On-line přístup:	https://www.tandfonline.com/doi/10.1080/2162402X.2025.2532226
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!